Abstract
With the emergence of new clinical trial data on disease-modifying therapies in several. Alzheimer’s disease (AD) studies, the Alzheimer’s Association convened individuals living with AD to gain their perspective on meaningfulness and new treatments. A total of 30 Alzheimer’s Association National Early Stage Advisory Group members participated in a focus group or an online survey to gain insights on what is wanted from a first-in-class treatment that could stop the progression of their disease at the earliest stage. Participants felt that researchers and regulators need to consider personal meaningfulness alongside clinical meaningfulness. At the same time, individuals living with AD felt that access, education, choice, and affordability were all important considerations moving forward.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Monica Moreno,
Chelsea R. Kline,
Kerry Lanigan,
Beth Kallmyer,
Kristen Clifford,
Sam Fazio | October 11, 2023